 Leigh Perreault
Concepts (326)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prediabetic State | 23 | 2023 | 219 | 6.970 |
Why?
| | Diabetes Mellitus, Type 2 | 47 | 2023 | 2096 | 5.260 |
Why?
| | Hypoglycemic Agents | 23 | 2023 | 1013 | 3.640 |
Why?
| | Insulin Resistance | 29 | 2023 | 1072 | 3.520 |
Why?
| | Blood Glucose | 31 | 2023 | 1828 | 2.850 |
Why?
| | Obesity | 25 | 2023 | 2508 | 2.800 |
Why?
| | Weight Loss | 13 | 2023 | 642 | 2.310 |
Why?
| | Cardiovascular Diseases | 15 | 2020 | 1727 | 2.240 |
Why?
| | Muscle, Skeletal | 19 | 2023 | 1473 | 2.150 |
Why?
| | Insulin | 19 | 2023 | 2080 | 2.010 |
Why?
| | Diabetes Mellitus | 11 | 2023 | 900 | 1.760 |
Why?
| | Sphingolipids | 6 | 2023 | 57 | 1.700 |
Why?
| | Benzhydryl Compounds | 3 | 2017 | 60 | 1.510 |
Why?
| | Glucose Intolerance | 8 | 2020 | 136 | 1.490 |
Why?
| | Diabetic Angiopathies | 3 | 2017 | 244 | 1.470 |
Why?
| | Triglycerides | 10 | 2022 | 467 | 1.450 |
Why?
| | Overweight | 7 | 2022 | 472 | 1.200 |
Why?
| | Diabetes Complications | 2 | 2019 | 211 | 1.150 |
Why?
| | Diglycerides | 5 | 2020 | 53 | 1.120 |
Why?
| | Glucosides | 2 | 2017 | 36 | 1.110 |
Why?
| | Glucagon-Like Peptide 1 | 3 | 2023 | 101 | 1.050 |
Why?
| | Life Style | 12 | 2020 | 430 | 1.050 |
Why?
| | Primary Health Care | 6 | 2023 | 1514 | 0.980 |
Why?
| | Metformin | 13 | 2023 | 276 | 0.960 |
Why?
| | Receptors, Gastrointestinal Hormone | 1 | 2023 | 5 | 0.900 |
Why?
| | Glucose Tolerance Test | 15 | 2021 | 343 | 0.880 |
Why?
| | Exercise | 10 | 2017 | 1644 | 0.870 |
Why?
| | Goals | 2 | 2021 | 147 | 0.830 |
Why?
| | Anti-Obesity Agents | 1 | 2023 | 45 | 0.830 |
Why?
| | Humans | 90 | 2023 | 114705 | 0.820 |
Why?
| | Adult | 50 | 2023 | 30553 | 0.820 |
Why?
| | Health Equity | 1 | 2023 | 53 | 0.800 |
Why?
| | Middle Aged | 41 | 2023 | 26738 | 0.780 |
Why?
| | Liver | 4 | 2014 | 1637 | 0.780 |
Why?
| | Nutrition Therapy | 1 | 2022 | 31 | 0.770 |
Why?
| | Adipose Tissue | 4 | 2023 | 545 | 0.730 |
Why?
| | Glucose Clamp Technique | 9 | 2021 | 181 | 0.720 |
Why?
| | Hyperglycemia | 4 | 2014 | 292 | 0.700 |
Why?
| | Primary Care Nursing | 1 | 2019 | 3 | 0.680 |
Why?
| | Male | 55 | 2023 | 55607 | 0.670 |
Why?
| | Female | 60 | 2023 | 59521 | 0.660 |
Why?
| | Microvessels | 1 | 2019 | 68 | 0.630 |
Why?
| | Insulin, Long-Acting | 1 | 2019 | 53 | 0.620 |
Why?
| | Peripheral Vascular Diseases | 1 | 2019 | 97 | 0.620 |
Why?
| | Obesity Management | 1 | 2018 | 8 | 0.620 |
Why?
| | Body Mass Index | 11 | 2023 | 1959 | 0.620 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2019 | 72 | 0.610 |
Why?
| | Infant, Newborn, Diseases | 1 | 2019 | 104 | 0.600 |
Why?
| | Awareness | 1 | 2019 | 93 | 0.600 |
Why?
| | Fasting | 4 | 2020 | 241 | 0.590 |
Why?
| | Risk Factors | 19 | 2023 | 8632 | 0.590 |
Why?
| | Precision Medicine | 1 | 2021 | 337 | 0.580 |
Why?
| | Weight Reduction Programs | 2 | 2017 | 94 | 0.560 |
Why?
| | Policy | 1 | 2018 | 137 | 0.560 |
Why?
| | Incretins | 2 | 2021 | 15 | 0.540 |
Why?
| | Risk Management | 1 | 2017 | 89 | 0.540 |
Why?
| | Rest | 2 | 2017 | 103 | 0.530 |
Why?
| | Choristoma | 1 | 2015 | 23 | 0.510 |
Why?
| | Sleep Deprivation | 5 | 2021 | 167 | 0.500 |
Why?
| | Insulin-Secreting Cells | 2 | 2010 | 317 | 0.500 |
Why?
| | Weight Gain | 4 | 2019 | 453 | 0.460 |
Why?
| | Lipid Metabolism | 4 | 2021 | 444 | 0.450 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2022 | 1214 | 0.440 |
Why?
| | Glucose | 4 | 2023 | 897 | 0.430 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 932 | 0.420 |
Why?
| | Phenols | 1 | 2013 | 82 | 0.410 |
Why?
| | Glucagon-Like Peptides | 2 | 2022 | 22 | 0.390 |
Why?
| | Physical Endurance | 5 | 2020 | 232 | 0.380 |
Why?
| | Aged | 17 | 2023 | 19074 | 0.370 |
Why?
| | Fenofibrate | 1 | 2011 | 24 | 0.360 |
Why?
| | Hospitalization | 1 | 2019 | 1752 | 0.360 |
Why?
| | Hypolipidemic Agents | 1 | 2011 | 86 | 0.350 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2010 | 44 | 0.340 |
Why?
| | Palmitates | 1 | 2009 | 16 | 0.340 |
Why?
| | Pyrazines | 1 | 2010 | 71 | 0.340 |
Why?
| | Biomarkers | 8 | 2023 | 3408 | 0.330 |
Why?
| | Energy Metabolism | 4 | 2021 | 731 | 0.330 |
Why?
| | Sleep | 4 | 2021 | 632 | 0.330 |
Why?
| | Athletes | 6 | 2020 | 328 | 0.320 |
Why?
| | Triazoles | 1 | 2010 | 131 | 0.320 |
Why?
| | Cross-Sectional Studies | 7 | 2023 | 4410 | 0.310 |
Why?
| | Ceramides | 3 | 2022 | 91 | 0.290 |
Why?
| | Sex Characteristics | 3 | 2021 | 641 | 0.290 |
Why?
| | Diabetic Nephropathies | 2 | 2020 | 234 | 0.290 |
Why?
| | Risk Reduction Behavior | 3 | 2023 | 201 | 0.290 |
Why?
| | Sodium-Glucose Transporter 2 | 2 | 2017 | 17 | 0.290 |
Why?
| | Sex Factors | 5 | 2018 | 1715 | 0.280 |
Why?
| | Absenteeism | 2 | 2018 | 40 | 0.270 |
Why?
| | Markov Chains | 2 | 2018 | 114 | 0.270 |
Why?
| | Health Services | 2 | 2018 | 103 | 0.260 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2022 | 486 | 0.260 |
Why?
| | Pilot Projects | 2 | 2021 | 1373 | 0.260 |
Why?
| | Adiponectin | 3 | 2018 | 213 | 0.260 |
Why?
| | Follow-Up Studies | 6 | 2021 | 4411 | 0.250 |
Why?
| | Circadian Rhythm | 3 | 2019 | 356 | 0.250 |
Why?
| | Lipids | 3 | 2015 | 580 | 0.250 |
Why?
| | Remission Induction | 3 | 2019 | 233 | 0.250 |
Why?
| | Young Adult | 11 | 2019 | 10471 | 0.240 |
Why?
| | Double-Blind Method | 4 | 2022 | 1660 | 0.240 |
Why?
| | Dietary Fats | 3 | 2020 | 287 | 0.230 |
Why?
| | Lipogenesis | 2 | 2017 | 56 | 0.220 |
Why?
| | Lipoprotein Lipase | 1 | 2004 | 54 | 0.220 |
Why?
| | Consensus | 3 | 2020 | 537 | 0.210 |
Why?
| | Socioeconomic Factors | 2 | 2018 | 1079 | 0.210 |
Why?
| | Computer Simulation | 2 | 2018 | 873 | 0.210 |
Why?
| | Physical Exertion | 1 | 2004 | 209 | 0.210 |
Why?
| | Healthy Lifestyle | 1 | 2023 | 30 | 0.210 |
Why?
| | Energy Intake | 4 | 2021 | 427 | 0.210 |
Why?
| | Diet, Reducing | 3 | 2017 | 76 | 0.200 |
Why?
| | Prevalence | 2 | 2019 | 2251 | 0.200 |
Why?
| | Biopsy | 3 | 2018 | 1036 | 0.200 |
Why?
| | Combined Modality Therapy | 4 | 2019 | 1121 | 0.200 |
Why?
| | Sarcolemma | 2 | 2020 | 29 | 0.190 |
Why?
| | Cluster Analysis | 1 | 2023 | 455 | 0.190 |
Why?
| | Endpoint Determination | 2 | 2019 | 68 | 0.190 |
Why?
| | Muscle Fibers, Skeletal | 2 | 2023 | 185 | 0.190 |
Why?
| | Nephrology | 1 | 2022 | 48 | 0.190 |
Why?
| | Cytosol | 2 | 2020 | 208 | 0.190 |
Why?
| | Glucose Transporter Type 4 | 1 | 2021 | 36 | 0.190 |
Why?
| | Ambulatory Care Facilities | 1 | 2023 | 213 | 0.180 |
Why?
| | Carnitine | 1 | 2021 | 62 | 0.180 |
Why?
| | Oxidation-Reduction | 3 | 2021 | 923 | 0.170 |
Why?
| | Risk Adjustment | 1 | 2020 | 76 | 0.170 |
Why?
| | Endocrinologists | 1 | 2020 | 12 | 0.170 |
Why?
| | New Zealand | 1 | 2019 | 41 | 0.170 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2019 | 47 | 0.170 |
Why?
| | Endoplasmic Reticulum | 2 | 2020 | 234 | 0.170 |
Why?
| | Cytosine | 1 | 2019 | 44 | 0.170 |
Why?
| | Adolescent | 8 | 2023 | 17853 | 0.160 |
Why?
| | Fatty Liver | 1 | 2021 | 211 | 0.160 |
Why?
| | United States | 9 | 2023 | 12186 | 0.160 |
Why?
| | Exercise Test | 3 | 2015 | 544 | 0.160 |
Why?
| | Liraglutide | 1 | 2019 | 27 | 0.160 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2019 | 151 | 0.160 |
Why?
| | Retinal Diseases | 1 | 2019 | 76 | 0.160 |
Why?
| | Models, Econometric | 1 | 2018 | 34 | 0.150 |
Why?
| | Colorado | 3 | 2023 | 4100 | 0.150 |
Why?
| | Referral and Consultation | 1 | 2023 | 635 | 0.150 |
Why?
| | Postprandial Period | 1 | 2019 | 87 | 0.150 |
Why?
| | Quinolizines | 1 | 1997 | 4 | 0.150 |
Why?
| | Drug Combinations | 1 | 2019 | 287 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2019 | 1842 | 0.150 |
Why?
| | Antiemetics | 1 | 1997 | 32 | 0.140 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2540 | 0.140 |
Why?
| | Nausea | 1 | 1997 | 101 | 0.140 |
Why?
| | Cholesterol, HDL | 2 | 2015 | 183 | 0.140 |
Why?
| | Health Resources | 1 | 2018 | 122 | 0.140 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 225 | 0.140 |
Why?
| | Vomiting | 1 | 1997 | 123 | 0.140 |
Why?
| | Hysterectomy | 1 | 1997 | 106 | 0.140 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 248 | 0.140 |
Why?
| | Odds Ratio | 1 | 2019 | 953 | 0.140 |
Why?
| | Treatment Outcome | 6 | 2021 | 9088 | 0.130 |
Why?
| | Body Weight | 3 | 2015 | 869 | 0.130 |
Why?
| | Patient-Centered Care | 1 | 2021 | 473 | 0.130 |
Why?
| | Patient Participation | 1 | 2019 | 359 | 0.130 |
Why?
| | Research Design | 2 | 2019 | 928 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2023 | 833 | 0.130 |
Why?
| | Exercise Therapy | 2 | 2017 | 352 | 0.130 |
Why?
| | Phosphatidylethanolamines | 1 | 2016 | 66 | 0.130 |
Why?
| | Eating | 2 | 2021 | 344 | 0.130 |
Why?
| | Kidney Diseases | 1 | 2019 | 350 | 0.130 |
Why?
| | Blotting, Western | 2 | 2016 | 1147 | 0.130 |
Why?
| | Cost-Benefit Analysis | 1 | 2018 | 544 | 0.130 |
Why?
| | Indoles | 1 | 1997 | 304 | 0.120 |
Why?
| | Phosphatidylcholines | 1 | 2016 | 133 | 0.120 |
Why?
| | Patient Compliance | 1 | 2019 | 525 | 0.120 |
Why?
| | Qualitative Research | 1 | 2019 | 936 | 0.120 |
Why?
| | Costs and Cost Analysis | 1 | 2015 | 196 | 0.120 |
Why?
| | Hypoglycemia | 1 | 2019 | 387 | 0.120 |
Why?
| | Sleep Apnea Syndromes | 1 | 2015 | 74 | 0.120 |
Why?
| | Income | 1 | 2015 | 167 | 0.120 |
Why?
| | Logistic Models | 1 | 2019 | 1841 | 0.120 |
Why?
| | Pneumonia | 1 | 2019 | 568 | 0.110 |
Why?
| | Health Personnel | 1 | 2019 | 574 | 0.110 |
Why?
| | Somatostatin | 1 | 2014 | 52 | 0.110 |
Why?
| | Employment | 1 | 2015 | 137 | 0.110 |
Why?
| | Recovery of Function | 2 | 2015 | 574 | 0.110 |
Why?
| | Smoking | 2 | 2012 | 1383 | 0.110 |
Why?
| | Fructose | 1 | 2014 | 100 | 0.110 |
Why?
| | Cost of Illness | 1 | 2015 | 254 | 0.110 |
Why?
| | Multicenter Studies as Topic | 1 | 2014 | 249 | 0.110 |
Why?
| | Aged, 80 and over | 3 | 2019 | 6347 | 0.110 |
Why?
| | Metabolic Diseases | 1 | 2014 | 98 | 0.110 |
Why?
| | Oxygen Consumption | 4 | 2016 | 588 | 0.110 |
Why?
| | C-Reactive Protein | 1 | 2015 | 362 | 0.110 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2012 | 47 | 0.100 |
Why?
| | Prospective Studies | 3 | 2019 | 6220 | 0.100 |
Why?
| | Mitochondria | 1 | 2018 | 747 | 0.100 |
Why?
| | Homeostasis | 1 | 2016 | 573 | 0.100 |
Why?
| | Depressive Disorder, Major | 1 | 2015 | 301 | 0.100 |
Why?
| | Models, Theoretical | 1 | 2016 | 515 | 0.100 |
Why?
| | Adult Children | 1 | 2011 | 21 | 0.100 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1395 | 0.100 |
Why?
| | Age Factors | 1 | 2018 | 2894 | 0.090 |
Why?
| | Placebos | 2 | 2009 | 197 | 0.090 |
Why?
| | Diabetes, Gestational | 1 | 2015 | 281 | 0.090 |
Why?
| | Adipocytes | 1 | 2012 | 188 | 0.090 |
Why?
| | Metabolomics | 1 | 2015 | 521 | 0.090 |
Why?
| | Health Behavior | 2 | 2023 | 704 | 0.090 |
Why?
| | Quality of Life | 3 | 2019 | 2353 | 0.090 |
Why?
| | Comorbidity | 1 | 2015 | 1448 | 0.090 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2019 | 1183 | 0.090 |
Why?
| | Sitagliptin Phosphate | 1 | 2010 | 30 | 0.090 |
Why?
| | Longevity | 1 | 2011 | 137 | 0.090 |
Why?
| | Family Health | 1 | 2011 | 193 | 0.090 |
Why?
| | Mitochondria, Muscle | 2 | 2021 | 93 | 0.080 |
Why?
| | C-Peptide | 1 | 2010 | 138 | 0.080 |
Why?
| | Tandem Mass Spectrometry | 1 | 2012 | 412 | 0.080 |
Why?
| | Delphi Technique | 2 | 2019 | 160 | 0.080 |
Why?
| | Menopause | 1 | 2011 | 271 | 0.080 |
Why?
| | Leisure Activities | 1 | 2008 | 25 | 0.070 |
Why?
| | Blood Pressure | 1 | 2014 | 1538 | 0.070 |
Why?
| | Body Composition | 1 | 2011 | 590 | 0.070 |
Why?
| | Postoperative Complications | 1 | 1997 | 2128 | 0.070 |
Why?
| | Risk Assessment | 3 | 2015 | 2968 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 1796 | 0.070 |
Why?
| | Mass Screening | 1 | 2013 | 1006 | 0.070 |
Why?
| | Cohort Studies | 4 | 2021 | 4895 | 0.070 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2012 | 3252 | 0.070 |
Why?
| | Fibrinogen | 2 | 2018 | 154 | 0.070 |
Why?
| | Aging | 1 | 2015 | 1618 | 0.060 |
Why?
| | Multivariate Analysis | 1 | 2009 | 1430 | 0.060 |
Why?
| | Regression Analysis | 2 | 2019 | 945 | 0.060 |
Why?
| | Retrospective Studies | 2 | 2019 | 12556 | 0.060 |
Why?
| | Incidence | 3 | 2019 | 2313 | 0.060 |
Why?
| | Gene Expression Profiling | 2 | 2023 | 1518 | 0.060 |
Why?
| | Prognosis | 2 | 2023 | 3330 | 0.060 |
Why?
| | Depression | 1 | 2012 | 1134 | 0.060 |
Why?
| | Health Expenditures | 1 | 1986 | 171 | 0.060 |
Why?
| | Metabolic Clearance Rate | 1 | 2004 | 102 | 0.060 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 4694 | 0.060 |
Why?
| | Alcohol Drinking | 1 | 2009 | 651 | 0.050 |
Why?
| | Parents | 1 | 2011 | 1186 | 0.050 |
Why?
| | Hormones | 1 | 2004 | 132 | 0.050 |
Why?
| | Menstrual Cycle | 1 | 2003 | 108 | 0.050 |
Why?
| | Eligibility Determination | 1 | 2023 | 60 | 0.050 |
Why?
| | Wakefulness | 2 | 2015 | 128 | 0.050 |
Why?
| | Lactic Acid | 1 | 2003 | 275 | 0.050 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1075 | 0.050 |
Why?
| | Disease Progression | 2 | 2019 | 2380 | 0.050 |
Why?
| | Citric Acid Cycle | 1 | 2021 | 43 | 0.050 |
Why?
| | Subcellular Fractions | 1 | 2021 | 78 | 0.050 |
Why?
| | Injections, Subcutaneous | 1 | 2021 | 134 | 0.050 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2020 | 48 | 0.050 |
Why?
| | Motor Activity | 2 | 2015 | 640 | 0.040 |
Why?
| | Kinetics | 1 | 2004 | 1551 | 0.040 |
Why?
| | Protective Agents | 1 | 2020 | 37 | 0.040 |
Why?
| | Education | 1 | 2020 | 95 | 0.040 |
Why?
| | Pregnancy | 2 | 2015 | 5520 | 0.040 |
Why?
| | Proprotein Convertase 9 | 1 | 2020 | 61 | 0.040 |
Why?
| | Stearoyl-CoA Desaturase | 2 | 2010 | 53 | 0.040 |
Why?
| | Time Factors | 3 | 2019 | 6116 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2013 | 1226 | 0.040 |
Why?
| | Poisson Distribution | 1 | 2019 | 71 | 0.040 |
Why?
| | Stakeholder Participation | 1 | 2019 | 73 | 0.040 |
Why?
| | E-Selectin | 1 | 2018 | 53 | 0.040 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2018 | 28 | 0.040 |
Why?
| | Subcutaneous Fat | 1 | 2019 | 70 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2018 | 105 | 0.040 |
Why?
| | Probability | 1 | 2019 | 289 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 150 | 0.040 |
Why?
| | Intra-Abdominal Fat | 1 | 2019 | 77 | 0.040 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2018 | 154 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2020 | 554 | 0.040 |
Why?
| | Diet | 3 | 2012 | 1080 | 0.040 |
Why?
| | Research | 1 | 2020 | 394 | 0.040 |
Why?
| | Leptin | 1 | 2018 | 210 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2017 | 3003 | 0.040 |
Why?
| | Adaptation, Physiological | 2 | 2010 | 483 | 0.030 |
Why?
| | Metabolome | 1 | 2019 | 282 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 386 | 0.030 |
Why?
| | Biological Transport | 1 | 2017 | 374 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2013 | 2387 | 0.030 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2016 | 84 | 0.030 |
Why?
| | Diet, Fat-Restricted | 1 | 2015 | 73 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2020 | 505 | 0.030 |
Why?
| | Kidney | 1 | 2022 | 1188 | 0.030 |
Why?
| | Melatonin | 1 | 2015 | 106 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2018 | 676 | 0.030 |
Why?
| | Fatty Acids | 1 | 2016 | 381 | 0.030 |
Why?
| | Calorimetry | 1 | 2013 | 60 | 0.030 |
Why?
| | Algorithms | 1 | 2020 | 1470 | 0.030 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2012 | 56 | 0.030 |
Why?
| | Risk | 1 | 2015 | 812 | 0.030 |
Why?
| | Sleep Wake Disorders | 1 | 2015 | 233 | 0.030 |
Why?
| | Glycerol | 1 | 2012 | 84 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2010 | 2553 | 0.030 |
Why?
| | Animals | 1 | 2013 | 31709 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 4624 | 0.020 |
Why?
| | Antidepressive Agents | 1 | 2012 | 195 | 0.020 |
Why?
| | Calorimetry, Indirect | 1 | 2010 | 69 | 0.020 |
Why?
| | Genetic Variation | 1 | 2015 | 870 | 0.020 |
Why?
| | Palmitic Acid | 1 | 2010 | 36 | 0.020 |
Why?
| | Polysomnography | 1 | 2010 | 136 | 0.020 |
Why?
| | Nicotine | 1 | 2012 | 265 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2320 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2012 | 360 | 0.020 |
Why?
| | Retinoid X Receptor gamma | 1 | 2009 | 4 | 0.020 |
Why?
| | PPAR alpha | 1 | 2009 | 52 | 0.020 |
Why?
| | Women's Health | 1 | 2011 | 271 | 0.020 |
Why?
| | Bicycling | 1 | 2010 | 86 | 0.020 |
Why?
| | Coronary Disease | 1 | 2011 | 348 | 0.020 |
Why?
| | Phospholipids | 1 | 2010 | 197 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1569 | 0.020 |
Why?
| | Reference Values | 1 | 2009 | 743 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2015 | 2086 | 0.020 |
Why?
| | Adiposity | 1 | 2012 | 458 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 923 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2011 | 680 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1760 | 0.020 |
Why?
| | Infant Care | 1 | 1986 | 42 | 0.020 |
Why?
| | Infertility | 1 | 1986 | 45 | 0.020 |
Why?
| | Health Promotion | 1 | 2011 | 686 | 0.020 |
Why?
| | Delivery, Obstetric | 1 | 1986 | 118 | 0.020 |
Why?
| | Maternal Health Services | 1 | 1986 | 79 | 0.010 |
Why?
| | Abortion, Induced | 1 | 1986 | 71 | 0.010 |
Why?
| | Contraception | 1 | 1986 | 117 | 0.010 |
Why?
| | Follicular Phase | 1 | 2003 | 36 | 0.010 |
Why?
| | Anaerobic Threshold | 1 | 2003 | 22 | 0.010 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2003 | 73 | 0.010 |
Why?
| | Luteal Phase | 1 | 2003 | 41 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2011 | 1880 | 0.010 |
Why?
| | Catecholamines | 1 | 2003 | 94 | 0.010 |
Why?
| | Heart Rate | 1 | 2003 | 709 | 0.010 |
Why?
| | Infant, Newborn | 1 | 1986 | 5047 | 0.010 |
Why?
|
|
Perreault's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|